PSMD4 and hepatocellular carcinoma: Survival analysis of patients who received both postsurgical TACE and sorafenib showed that low MCB1 expression in HCC tissues was correlated with longer OS, suggesting that MCB1 could be used as a potential marker for the selection of patients for TACE plus sorafenib, which has clinical importance in the current practice of HCC treatment.